BLINCYTO

This brand name is authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, South Africa, Turkey, UK.

Active ingredients

The drug BLINCYTO contains one active pharmaceutical ingredient (API):

1	Blinatumomab UNII 4FR53SIF3A - BLINATUMOMAB
	Blinatumomab is a bispecific T-cell engager molecule that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells. It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells. The anti-tumour activity of blinatumomab immunotherapy is not dependent on T-cells bearing a specific TCR or on peptide antigens presented by cancer cells, but is polyclonal in nature and independent of human leukocyte antigen (HLA) molecules on target cells. Blinatumomab mediates the formation of a cytolytic synapse between the T-cell and the tumour cell, releasing proteolytic enzymes to kill both proliferating and resting target cells.
	Read more about Blinatumomab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BLINCYTO Powder and solution for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX07	Blinatumomab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11115B, 11116C, 11117D, 11118E, 11119F, 11120G, 11799B, 11814T, 11850Q, 11867N
BR	Câmara de Regulação do Mercado de Medicamentos	544117080004101
CA	Health Products and Food Branch	02450283
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	169-MBE-1120
EE	Ravimiamet	1706048
FI	Lääkealan turvallisuus- ja kehittämiskeskus	462169
FR	Base de données publique des médicaments	62003633
GB	Medicines & Healthcare Products Regulatory Agency	311441
HK	Department of Health Drug Office	65074
IL	מִשְׂרַד הַבְּרִיאוּת	7802
JP	医薬品医療機器総合機構	4291445D1029
LT	Valstybinė vaistų kontrolės tarnyba	1078868
NL	Z-Index G-Standaard, PRK	129704
PL	Rejestru Produktów Leczniczych	100358980
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W62507001
SG	Health Sciences Authority	15103P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699862270021
ZA	Health Products Regulatory Authority	54/26/0736